These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

916 related items for PubMed ID: 26677785

  • 1. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy.
    Dudnik E, Siegal T, Zach L, Allen AM, Flex D, Yust-Katz S, Limon D, Hirsch FR, Peled N.
    J Clin Neurosci; 2016 Apr; 26():46-9. PubMed ID: 26677785
    [Abstract] [Full Text] [Related]

  • 2. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E.
    Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
    [Abstract] [Full Text] [Related]

  • 3. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
    Crinò L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T, Mok T, Spigel D, Felip E, Nishio M, Scagliotti G, Branle F, Emeremni C, Quadrigli M, Zhang J, Shaw AT.
    J Clin Oncol; 2016 Aug 20; 34(24):2866-73. PubMed ID: 27432917
    [Abstract] [Full Text] [Related]

  • 4. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
    Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT.
    Lancet Oncol; 2016 Apr 20; 17(4):452-463. PubMed ID: 26973324
    [Abstract] [Full Text] [Related]

  • 5. Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.
    Gainor JF, Tan DS, De Pas T, Solomon BJ, Ahmad A, Lazzari C, de Marinis F, Spitaleri G, Schultz K, Friboulet L, Yeap BY, Engelman JA, Shaw AT.
    Clin Cancer Res; 2015 Jun 15; 21(12):2745-52. PubMed ID: 25724526
    [Abstract] [Full Text] [Related]

  • 6. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
    Califano R, Greystoke A, Lal R, Thompson J, Popat S.
    Lung Cancer; 2017 Sep 15; 111():51-58. PubMed ID: 28838397
    [Abstract] [Full Text] [Related]

  • 7. Optimal management of ALK-positive NSCLC progressing on crizotinib.
    Metro G, Tazza M, Matocci R, Chiari R, Crinò L.
    Lung Cancer; 2017 Apr 15; 106():58-66. PubMed ID: 28285695
    [Abstract] [Full Text] [Related]

  • 8. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.
    Lancet Oncol; 2014 Sep 15; 15(10):1119-28. PubMed ID: 25153538
    [Abstract] [Full Text] [Related]

  • 9. Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.
    Kiura K, Imamura F, Kagamu H, Matsumoto S, Hida T, Nakagawa K, Satouchi M, Okamoto I, Takenoyama M, Fujisaka Y, Kurata T, Ito M, Tokushige K, Hatano B, Nishio M.
    Jpn J Clin Oncol; 2018 Apr 01; 48(4):367-375. PubMed ID: 29474558
    [Abstract] [Full Text] [Related]

  • 10. Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.
    Tan DS, Araújo A, Zhang J, Signorovitch J, Zhou ZY, Cai X, Liu G.
    J Thorac Oncol; 2016 Sep 01; 11(9):1550-7. PubMed ID: 27288979
    [Abstract] [Full Text] [Related]

  • 11. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K, Kolesar JM.
    Am J Health Syst Pharm; 2015 Sep 01; 72(17):1456-62. PubMed ID: 26294238
    [Abstract] [Full Text] [Related]

  • 12. Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study.
    Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, Guérin A.
    Adv Ther; 2017 May 01; 34(5):1145-1156. PubMed ID: 28405961
    [Abstract] [Full Text] [Related]

  • 13. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
    Toyokawa G, Seto T, Takenoyama M, Ichinose Y.
    Cancer Metastasis Rev; 2015 Dec 01; 34(4):797-805. PubMed ID: 26342831
    [Abstract] [Full Text] [Related]

  • 14. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
    Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, Zhou C, Shreeve SM, Selaru P, Polli A, Schnell P, Wilner KD, Wiltshire R, Camidge DR, Crinò L.
    J Clin Oncol; 2015 Jun 10; 33(17):1881-8. PubMed ID: 25624436
    [Abstract] [Full Text] [Related]

  • 15. Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset.
    Hida T, Satouchi M, Nakagawa K, Seto T, Matsumoto S, Kiura K, Nokihara H, Murakami H, Tokushige K, Hatano B, Nishio M.
    Jpn J Clin Oncol; 2017 Jul 01; 47(7):618-624. PubMed ID: 28369553
    [Abstract] [Full Text] [Related]

  • 16. Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.
    Won B, Mambetsariev I, Salgia R.
    BMC Cancer; 2016 Aug 02; 16():568. PubMed ID: 27480287
    [Abstract] [Full Text] [Related]

  • 17. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
    Mok TSK, Crino L, Felip E, Salgia R, De Pas T, Tan DSW, Chow LQM.
    Cancer Treat Rev; 2017 Apr 02; 55():181-189. PubMed ID: 28427013
    [Abstract] [Full Text] [Related]

  • 18. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
    Muller IB, De Langen AJ, Honeywell RJ, Giovannetti E, Peters GJ.
    Expert Rev Anticancer Ther; 2016 Apr 02; 16(2):147-57. PubMed ID: 26654422
    [Abstract] [Full Text] [Related]

  • 19. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.
    Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, Contessa JN.
    J Clin Oncol; 2016 Jan 10; 34(2):123-9. PubMed ID: 26438117
    [Abstract] [Full Text] [Related]

  • 20. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
    Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, Huber RM, West HL, Groen HJM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz-Ares Rodríguez LG, Smit EF, Kim ES, Reichmann W, Haluska FG, Kerstein D, Camidge DR.
    J Clin Oncol; 2017 Aug 01; 35(22):2490-2498. PubMed ID: 28475456
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.